A common strategy used in clinical trials targeting the IFN-I pathway is to average the expression of four genes (IFI27, IFI44, IFI44L, and RSAD2) to classify patients with SLE according to IFN activity.16 This evidence concerns the gene IFNA1 and systemic lupus erythematosus.